



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/707172/2021

European Medicines Agency decision P/0553/2021

of 31 December 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for molnupiravir (EMA-002940-PIP02-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0553/2021

of 31 December 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for molnupiravir (EMA-002940-PIP02-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc. on 9 August 2021 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 November 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for molnupiravir, capsule, hard, age-appropriate dosage form, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for molnupiravir, capsule, hard, age-appropriate dosage form, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Merck Sharp & Dohme (Europe), Inc. Clos du Lynx, 5, 1200 – Brussels, Belgium.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/596883/2021
Amsterdam, 12 November 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-002940-PIP02-21

Scope of the application

Active substance(s):

Molnupiravir

Condition(s):

Prevention of coronavirus disease 2019 (COVID-19)

Pharmaceutical form(s):

Capsule, hard

Age-appropriate dosage form

Route(s) of administration:

Oral use

Gastric use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc. submitted for agreement to the European Medicines Agency on 9 August 2021 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 14 September 2021.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Prevention of coronavirus disease 2019 (COVID-19).

2.1.1. Indication(s) targeted by the PIP

Prevention of coronavirus disease 2019 (COVID-19).

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Capsule, hard

Age-appropriate dosage form.

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 (same as study 1 in EMEA-002940-PIP01-20) Development of an age-appropriate dosage form (granules) for use in children from birth to less than 12 years of age.
Non-clinical studies	1	Study 2 (same as study 2 in EMEA-002940-PIP01-20) Juvenile toxicity rat study.
Clinical studies	1	Study 3 (same as study 3 in EMEA-002940-PIP01-20) Multicentre, open-label study to evaluate the pharmacokinetics, safety and efficacy of molnupiravir (MK-4482) in children from birth to less than 18 years of age (including premature infants born at least at 32 weeks gestational age) with mild or moderate coronavirus disease 2019.
Extrapolation, modelling and simulation	2	Study 4 Population PK modelling and PK/PD exposure-response study to select the molnupiravir (MK-4482) doses across weight bands in children

studies		from birth to less than 18 years with coronavirus disease 2019 and healthy children from birth to less than 18 years of age for the prevention of coronavirus disease 2019. Study 5 Extrapolation study of efficacy and safety of molnupiravir (MK-4482) from healthy adults to healthy children from birth to less than 18 years of age for the prevention of coronavirus disease 2019.
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By November 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes